Takeda Pharmaceutical Company Limited (4502) Gross Profit 2023–2026

Name: Takeda Pharmaceutical Company Limited (4502) gross profit history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Takeda Pharmaceutical Company Limited annual gross profit for fiscal 2026 was JPY 2.93 trillion, a decrease of 2.2% from JPY 3.00 trillion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

4502 Annual Gross Profit

Gross Profit (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Gross Profit	JPY 2.93T	JPY 3.00T	JPY 2.84T	JPY 2.78T

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4502 Quarterly Gross Profit

Gross Profit (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Gross Profit	JPY 813.2B	JPY 688.8B	JPY 790.5B	JPY 732.7B	JPY 722.0B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Gross Profit at Comparable Companies

4507 Gross Profit — Shionogi & Co., Ltd.
4523 Gross Profit — Eisai Co., Ltd.
4151 Gross Profit — Kyowa Kirin Co., Ltd.
4506 Gross Profit — Sumitomo Pharma Co., Ltd.
1276 Gross Profit — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
4540 Gross Profit — Tsumura & Co.

More 4502 metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow

All 4502 financial statements → Interactive 4502 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.